PAC Antibody

PAC-1 Antibody Targeting CD41/CD61 (Platelet Glycoprotein IIb/IIIa)

Target: The PAC-1 antibody specifically recognizes an activation-dependent conformational epitope on the CD41/CD61 complex (integrin αIIbβ3), a receptor critical for platelet aggregation .

Key Features:

• Clone: PAC-1 (mouse monoclonal IgMκ) .

• Applications:

  • Flow cytometry (detection of activated platelets) .

  • Immunoprecipitation and immunofluorescence .

• Mechanism: Binds selectively to the activated form of integrin αIIbβ3, which undergoes conformational changes during platelet activation .

Research Findings:

• PAC-1 antibodies are used to study thrombosis and hemostasis. For example, they detect activated platelets in cardiovascular diseases .

• In flow cytometry, PAC-1 shows negligible binding to resting platelets but high specificity for activated platelets (e.g., post-PHA stimulation) .

Table 2: Anti-PAC1 Receptor Antibodies

Anti-pac Antibodies Targeting PACC1

Target: PACC1 (proton-activated chloride channel 1), a membrane protein regulating ion transport .

Key Features:

• Commercial Availability: 177 anti-pac antibody products across 15 suppliers target human PACC1 .

• Applications:

  • Western blotting .

  • Membrane-associated protein studies .

Protein-Antibody Conjugates (PACs) in Therapeutics

PACs are nanoparticle-based systems combining antibodies with protein payloads for targeted delivery . While not antibodies themselves, they utilize antibodies for cell-specific targeting:

• Structure: Spherical polymer brushes loaded with proteins (e.g., GFP) and surface-conjugated antibodies .

• Efficacy: Demonstrated high payload-to-antibody ratio (PAR) (~15–17,200:1) and cell-specific delivery in CD4+ leukemia models .